Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Haemonetics ( (HAE) ) has shared an update.
Haemonetics Corporation announced that longtime director Charles J. Dockendorff, who has served on its Board of Directors since 2014, notified the company on April 27, 2026, that he will not stand for re-election at the 2026 Annual Meeting of Shareholders. Dockendorff, currently a member of the Audit Committee and the Governance and Compliance Committee, will continue in his board and committee roles until the meeting, and the company stated his decision is not due to any disagreement with Haemonetics.
The most recent analyst rating on (HAE) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Haemonetics stock, see the HAE Stock Forecast page.
Spark’s Take on HAE Stock
According to Spark, TipRanks’ AI Analyst, HAE is a Neutral.
The score is driven primarily by solid profitability and strong cash generation alongside a positive earnings outlook with raised EPS/FCF guidance. Offsetting these are the sharp TTM revenue decline and higher leverage, while technical indicators remain mixed and suggest limited momentum.
To see Spark’s full report on HAE stock, click here.
More about Haemonetics
Haemonetics Corporation is a medical technology company that provides blood and plasma collection systems, transfusion management solutions, and related devices and software to healthcare providers, blood centers, and plasma collection facilities. The company focuses on supporting critical blood management and plasma supply chains across global healthcare markets.
Average Trading Volume: 810,187
Technical Sentiment Signal: Sell
Current Market Cap: $2.79B
See more data about HAE stock on TipRanks’ Stock Analysis page.